Skip to main content
Clinical Trials/EUCTR2021-003388-90-NL
EUCTR2021-003388-90-NL
Active, Not Recruiting
Phase 1

Prospective monitoring of immune response following COVID-19 vaccination in children with cancer - VACCinATE

Princess Máxima Center for Pediatric Oncology0 sites130 target enrollmentJune 21, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Children with cancer, receiving COVID-19 vaccination
Sponsor
Princess Máxima Center for Pediatric Oncology
Enrollment
130
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 21, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Princess Máxima Center for Pediatric Oncology

Eligibility Criteria

Inclusion Criteria

  • \-Willing to receive routine COVID\-19 vaccination with Pfizer or Moderna vaccine as part of the national vaccination program (cohort I)
  • \-Having received SARS\-CoV\-2 vaccination with Pfizer or Moderna as part of the national vaccination program with the last vaccination less than 6 weeks before study entry (cohort II \+ cohort III \+ cohort IV)
  • \-Written informed consent
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 130
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range 0
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range 0

Exclusion Criteria

  • \-History of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component of the study intervention
  • \-Not able to give informed consent (e.g. language problems, illiteracy)

Outcomes

Primary Outcomes

Not specified

Similar Trials